Results 81 to 90 of about 15,424 (278)

Checkpoint inhibitors: What gastroenterologists need to know. [PDF]

, 2018
Checkpoint inhibitors are increasingly being used in clinical practice. They can cause various gastrointestinal, hepatic and pancreatic side effects. As these side effects can be serious, appropriate management is essential.
Ahmed, Monjur
core   +1 more source

Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models

Proceedings of the National Academy of Sciences, 2023
Immune checkpoint blockers (ICBs) have failed in all phase III glioblastoma trials. Here, we found that ICBs induce cerebral edema in some patients and mice with glioblastoma. Through single-cell RNA sequencing, intravital imaging, and CD8 + T cell blocking studies in mice, we demonstrated that this edema results ...
Datta, Meenal, Chatterjee, Sampurna, Perez, Elizabeth M., Gritsch, Simon, Roberge, Sylvie, Duquette, Mark, Chen, Ivy X., Naxerova, Kamila, Kumar, Ashwin S., Ghosh, Mitrajit, Emblem, Kyrre E., Ng, Mei R., Ho, William W., Kumar, Pragya, Krishnan, Shanmugarajan, Dong, Xinyue, Speranza, Maria C., Neagu, Martha R., Iorgulescu, J. Bryan, Huang, Raymond Y., Youssef, Gilbert, Reardon, David A., Sharpe, Arlene H., Freeman, Gordon J., Suvà, Mario L., Xu, Lei, Jain, Rakesh K.   +26 more
openaire   +2 more sources

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Deubiquitinating Enzyme: A Potential Secondary Checkpoint of Cancer Immunity

Frontiers in Oncology, 2020
The efficacy of cancer immunotherapy depends on the fine interplay between tumoral immune checkpoints and host immune system. However, the up-to-date clinical performance of checkpoint blockers in cancer therapy revealed that higher-level regulation ...
Xing Huang, Xing Huang, Xing Huang, Xiaozhen Zhang, Xiaozhen Zhang, Xiaozhen Zhang, Jian Xu, Jian Xu, Jian Xu, Xun Wang, Xun Wang, Xun Wang, Gang Zhang, Gang Zhang, Gang Zhang, Tianyu Tang, Tianyu Tang, Tianyu Tang, Xiaochao Shen, Xiaochao Shen, Xiaochao Shen, Tingbo Liang, Tingbo Liang, Tingbo Liang, Xueli Bai, Xueli Bai, Xueli Bai   +26 more
doaj   +1 more source

Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment

Cells, 2022
The success of anticancer treatments relies on a long-term response which can be mediated by the immune system. Thus, the concept of immunogenic cell death (ICD) describes the capacity of dying cancer cells, under chemotherapy or physical stress, to ...
Nicolas Roussot, François Ghiringhelli, Cédric Rébé   +2 more
doaj   +1 more source

Immune targets in the tumor microenvironment treated by radiotherapy. [PDF]

, 2019
Radiotherapy (RT), the major anti-cancer modality for more than half of cancer patients after diagnosis, has the advantage of local tumor control with relatively less systematic side effects comparing to chemotherapy.
Li, Jian Jian, Ozpiskin, Omer M, Zhang, Lu   +2 more
core  

Rusty microglia: trainers of innate immunity in Alzheimer's disease [PDF]

, 2018
Alzheimer's disease, the most common form of dementia, is marked by progressive cognitive and functional impairment believed to reflect synaptic and neuronal loss.
Adonis Sfera, Adonis Sfera, Amy I. Price, Carolina Osorio, Eddie Diaz, Michael Cummings, Roberto Gradini   +6 more
core   +2 more sources

Novel technologies for applying immune checkpoint blockers

Cancer cells develop several ways to subdue the immune system among others via upregulation of inhibitory immune checkpoint (ICP) proteins. These ICPs paralyze immune effector cells and thereby enable unfettered tumor growth. Monoclonal antibodies (mAbs) that block ICPs can prevent immune exhaustion.
Awad, Robin Maximilian, Breckpot, Karine
openaire   +3 more sources

A Case of Acute Heart Failure due to Immune Checkpoint Blocker Nivolumab

Cardiology Research, 2019
Immune checkpoint inhibitors can be potentially cardiotoxic. It has not been frequently reported in the literature. Cardiomyopathy with these agents can have early onset and may start with non-specific symptoms like fatigue, weakness before presenting with obvious features of acute heart failure.
Sharma, Munish, Suero-Abreu, Giselle A., Kim, Bernard   +2 more
openaire   +3 more sources